Skip to content
Research Article Open access CC BY 4.0

Escalating BMI Associated With the Complex Pharmacology of Propranolol: A Case Report

Deena M. S. Barrouq, Tareq Irshaidat

Journal of Advances in Medical and Pharmaceutical Sciences · pp. 19–24 · Published 30 Oct 2020

10.9734/jamps/2020/v22i830187

Abstract

Background: Improving the awareness of the public about the body weight and the body mass index (BMI) criteria is very important as increased body weight may be associated with an increased risk for many dangerous diseases and health complications. Propranolol is generally prescribed for tachycardia while its most common side effects are bradycardia and masking hypoglycemia. Case Presentation: A tachycardia was diagnosed in a young overweight woman and treated successfully with propranolol but this treatment, unpredictably, was associated with a rapid increase in the weight that classified her as obese. Discussion: The physical (body weight and heart rate) and the biochemical (blood glucose level) monitoring and analysis including the lifestyle provided a deeper insight into the principal details and helped to design a personalized treatment protocol.   Conclusion: A therapeutic dose of propranolol could be linked to uncommon mounting weight change which was associated with a decrease in the blood glucose level and an appetite enhancement.

Tachycardia propranolol beta-blocker appetite weight gain obesity.

References (16)

  1. 1 Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women [DOI]
  2. 2 Worldwide prevalence of hypertension [DOI]
  3. 3 Blaming the Brain for Obesity: Integration of Hedonic and Homeostatic Mechanisms [DOI]
  4. 4 Medications that cause weight gain and alternatives in Canada: a narrative review [DOI]
  5. 5 Prescription Medications: A Modifiable Contributor to Obesity [DOI]
  6. 6 Propranolol Promotes Glucose Dependence and Synergizes with Dichloroacetate for Anti-Cancer Activity in HNSCC [DOI]
  7. 7 Excess Body Mass Index-Years, a Measure of Degree and Duration of Excess Weight, and Risk for Incident Diabetes [DOI]
  8. 8 Appetite control: hormones or diet strategies? [DOI]
  9. 9 Clinical Pharmacokinetics of Propranolol Hydrochloride: A Review [DOI]
  10. 10 Long term propranolol treatment and changes in body weight after myocardial infarction. [DOI]
  11. 11 Beta-adrenergic blockade increases GLUT4 and improves glycemic control in insulin-treated diabetic Wistar rats [DOI]
  12. 12 Psychotropic Medication-induced Weight Gain or Loss Looked through the Lens of Age and Psychiatric Diagnoses: A Narrative Review [DOI]
  13. 13 Novel Association between Gemfibrozil and Dyslipidemia: A Case Report [DOI]
  14. 14 TACHYCARDIA, DIABETES, AND ILLNESS PSYCHOLOGY INTERPLAY AT THE EDGE: A CASE REPORT. [DOI]
  15. 15 Meal plan prescription, biochemical parameters, and practicality in poorly controlled type-II diabetes mellitus patients [DOI]
  16. 16 The Association between Therapeutic Drug Classes and Weight Change in Patients Attending a Medically Supervised Weight Loss Clinic

Cited by 1

A Case Report with a Mini-Review of the Literature on the Overeating and Weight Gain Due to Propranolol.

Rabia Kevser Boyraz, Ebru Şahan, I. Kırpınar · Psychiatria Danubina · 2021

Related research

Article metrics

Real usage data collected on this platform.

64

Page views

0

PDF downloads

40

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.